SPONSOR
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Total Trials
6
Recruiting
6
Phases
Phase 1, Phase 2, Phase 3, Phase 1
Conditions studied: Advanced Lung CancerMetastatic Breast CancerRecurrent Breast CancerAdvanced MalignanciesGraft-versus-host DiseaseAdvanced CancersMyeloid MalignancyPlexiform Neurofibroma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is a clinical research sponsor with 6 registered studies on ClinicalTrials.gov, of which 6 are actively recruiting participants. Research covers conditions including Advanced Lung Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies.
The trial portfolio spans Phase 1, Phase 2, Phase 3, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
How many clinical trials has Chia Tai Tianqing Pharmaceutical Group Co., Ltd. sponsored?
ClinicalMetric currently tracks 6 clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., of which 6 are actively recruiting participants. These trials cover conditions including Advanced Lung Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Chia Tai Tianqing Pharmaceutical Group Co., Ltd. research focus on?
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. clinical trials span Advanced Lung Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies, Graft-versus-host Disease, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 3, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Chia Tai Tianqing Pharmaceutical Group Co., Ltd. clinical trial?
To participate in a Chia Tai Tianqing Pharmaceutical Group Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Chia Tai Tianqing Pharmaceutical Group Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT07367529 Phase 1, Phase 2
Recruiting
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
Advanced Lung Cancer
NCT06202261 Phase 1, Phase 2
Recruiting
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Metastatic Breast Cancer
NCT06682169 Phase 3
Recruiting
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Graft-versus-host Disease
NCT06413953 Phase 1
Recruiting
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
Advanced Cancers
NCT07011186 Phase 1, Phase 2
Recruiting
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
Myeloid Malignancy
NCT07407803 Phase 3
Recruiting
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
Plexiform Neurofibroma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology